866-997-4948(US-Canada Toll Free)

United States Antidiabetic SGLT-2 Inhibitor Market Report 2017

Published By :

QYResearch

Published Date : Jan 2017

Category :

Pharmaceutical

No. of Pages : 113 Pages

Notes:
Sales, means the sales volume of Antidiabetic SGLT-2 Inhibitor
Revenue, means the sales value of Antidiabetic SGLT-2 Inhibitor

This report studies sales (consumption) of Antidiabetic SGLT-2 Inhibitor in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
Anderson Hay & Grain Inc.
Border Valley
Sanofi
Johnson & Johnson
Bristol-Myers Squibb
AstraZeneca
Boehringer Ingelheim
GlaxoSmithKline
Pfizer
Takeda Pharmaceuticals
Eli Lilly
Merck & Co.
Novo Nordisk

Market Segment by States, covering
California
Texas
New York
Florida
Illinois
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Canagliflozin
Empagliflozin
Dapagliflozin
Split by applications, this report focuses on sales, market share and growth rate of Antidiabetic SGLT-2 Inhibitor in each application, can be divided into
Hospital
Clinic

Table of Contents

United States Antidiabetic SGLT-2 Inhibitor Market Report 2017
1 Antidiabetic SGLT-2 Inhibitor Overview
1.1 Product Overview and Scope of Antidiabetic SGLT-2 Inhibitor
1.2 Classification of Antidiabetic SGLT-2 Inhibitor
1.2.1 Canagliflozin
1.2.2 Empagliflozin
1.2.3 Dapagliflozin
1.3 Application of Antidiabetic SGLT-2 Inhibitor
1.3.1 Hospital
1.3.2 Clinic
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Antidiabetic SGLT-2 Inhibitor (2011-2021)
1.4.1 United States Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2011-2021)
1.4.2 United States Antidiabetic SGLT-2 Inhibitor Revenue and Growth Rate (2011-2021)

2 United States Antidiabetic SGLT-2 Inhibitor Competition by Manufacturers
2.1 United States Antidiabetic SGLT-2 Inhibitor Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Antidiabetic SGLT-2 Inhibitor Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Antidiabetic SGLT-2 Inhibitor Average Price by Manufactures (2015 and 2016)
2.4 Antidiabetic SGLT-2 Inhibitor Market Competitive Situation and Trends
2.4.1 Antidiabetic SGLT-2 Inhibitor Market Concentration Rate
2.4.2 Antidiabetic SGLT-2 Inhibitor Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion

3 United States Antidiabetic SGLT-2 Inhibitor Sales (Volume) and Revenue (Value) by States (2011-2016)
3.1 United States Antidiabetic SGLT-2 Inhibitor Sales and Market Share by States (2011-2016)
3.2 United States Antidiabetic SGLT-2 Inhibitor Revenue and Market Share by States (2011-2016)
3.3 United States Antidiabetic SGLT-2 Inhibitor Price by States (2011-2016)

4 United States Antidiabetic SGLT-2 Inhibitor Sales (Volume) and Revenue (Value) by Type (2011-2016)
4.1 United States Antidiabetic SGLT-2 Inhibitor Sales and Market Share by Type (2011-2016)
4.2 United States Antidiabetic SGLT-2 Inhibitor Revenue and Market Share by Type (2011-2016)
4.3 United States Antidiabetic SGLT-2 Inhibitor Price by Type (2011-2016)
4.4 United States Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Type (2011-2016)

5 United States Antidiabetic SGLT-2 Inhibitor Sales (Volume) by Application (2011-2016)
5.1 United States Antidiabetic SGLT-2 Inhibitor Sales and Market Share by Application (2011-2016)
5.2 United States Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Application (2011-2016)
5.3 Market Drivers and Opportunities

6 United States Antidiabetic SGLT-2 Inhibitor Manufacturers Profiles/Analysis
6.1 Anderson Hay & Grain Inc.
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.1.2.1 Canagliflozin
6.1.2.2 Empagliflozin
6.1.3 Anderson Hay & Grain Inc. Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.1.4 Main Business/Business Overview
6.2 Border Valley
6.2.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.2.2.1 Canagliflozin
6.2.2.2 Empagliflozin
6.2.3 Border Valley Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.2.4 Main Business/Business Overview
6.3 Sanofi
6.3.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.3.2.1 Canagliflozin
6.3.2.2 Empagliflozin
6.3.3 Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.3.4 Main Business/Business Overview
6.4 Johnson & Johnson
6.4.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.4.2.1 Canagliflozin
6.4.2.2 Empagliflozin
6.4.3 Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.4.4 Main Business/Business Overview
6.5 Bristol-Myers Squibb
6.5.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.5.2.1 Canagliflozin
6.5.2.2 Empagliflozin
6.5.3 Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.5.4 Main Business/Business Overview
6.6 AstraZeneca
6.6.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.6.2.1 Canagliflozin
6.6.2.2 Empagliflozin
6.6.3 AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.6.4 Main Business/Business Overview
6.7 Boehringer Ingelheim
6.7.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.7.2.1 Canagliflozin
6.7.2.2 Empagliflozin
6.7.3 Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.7.4 Main Business/Business Overview
6.8 GlaxoSmithKline
6.8.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.8.2.1 Canagliflozin
6.8.2.2 Empagliflozin
6.8.3 GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.8.4 Main Business/Business Overview
6.9 Pfizer
6.9.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.9.2.1 Canagliflozin
6.9.2.2 Empagliflozin
6.9.3 Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.9.4 Main Business/Business Overview
6.10 Takeda Pharmaceuticals
6.10.2 Antidiabetic SGLT-2 Inhibitor Product Type, Application and Specification
6.10.2.1 Canagliflozin
6.10.2.2 Empagliflozin
6.10.3 Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
6.10.4 Main Business/Business Overview
6.11 Eli Lilly
6.12 Merck & Co.
6.13 Novo Nordisk

7 Antidiabetic SGLT-2 Inhibitor Manufacturing Cost Analysis
7.1 Antidiabetic SGLT-2 Inhibitor Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Antidiabetic SGLT-2 Inhibitor Major Manufacturers in 2015
8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List

10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change

11 United States Antidiabetic SGLT-2 Inhibitor Market Forecast (2016-2021)
11.1 United States Antidiabetic SGLT-2 Inhibitor Sales, Revenue Forecast (2016-2021)
11.2 United States Antidiabetic SGLT-2 Inhibitor Sales Forecast by Type (2016-2021)
11.3 United States Antidiabetic SGLT-2 Inhibitor Sales Forecast by Application (2016-2021)
11.4 Antidiabetic SGLT-2 Inhibitor Price Forecast (2016-2021)

12 Research Findings and Conclusion

13 Appendix
Methodology
Analyst Introduction
Data Source

List of Table

List of Tables and Figures

Figure Picture of Antidiabetic SGLT-2 Inhibitor
Table Classification of Antidiabetic SGLT-2 Inhibitor
Figure United States Sales Market Share of Antidiabetic SGLT-2 Inhibitor by Type in 2015
Figure Canagliflozin Picture
Figure Empagliflozin Picture
Figure Dapagliflozin Picture
Table Application of Antidiabetic SGLT-2 Inhibitor
Figure United States Sales Market Share of Antidiabetic SGLT-2 Inhibitor by Application in 2015
Figure Hospital Examples
Figure Clinic Examples
Figure United States Antidiabetic SGLT-2 Inhibitor Sales and Growth Rate (2011-2021)
Figure United States Antidiabetic SGLT-2 Inhibitor Revenue and Growth Rate (2011-2021)
Table United States Antidiabetic SGLT-2 Inhibitor Sales of Key Manufacturers (2015 and 2016)
Table United States Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers
Figure 2016 Antidiabetic SGLT-2 Inhibitor Sales Share by Manufacturers
Table United States Antidiabetic SGLT-2 Inhibitor Revenue by Manufacturers (2015 and 2016)
Table United States Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers
Table 2016 United States Antidiabetic SGLT-2 Inhibitor Revenue Share by Manufacturers
Table United States Market Antidiabetic SGLT-2 Inhibitor Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Antidiabetic SGLT-2 Inhibitor Average Price of Key Manufacturers in 2015
Figure Antidiabetic SGLT-2 Inhibitor Market Share of Top 3 Manufacturers
Figure Antidiabetic SGLT-2 Inhibitor Market Share of Top 5 Manufacturers
Table United States Antidiabetic SGLT-2 Inhibitor Sales by States (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Sales Share by States (2011-2016)
Figure United States Antidiabetic SGLT-2 Inhibitor Sales Market Share by States in 2015
Table United States Antidiabetic SGLT-2 Inhibitor Revenue and Market Share by States (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Revenue Share by States (2011-2016)
Figure Revenue Market Share of Antidiabetic SGLT-2 Inhibitor by States (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Price by States (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Sales by Type (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Sales Share by Type (2011-2016)
Figure United States Antidiabetic SGLT-2 Inhibitor Sales Market Share by Type in 2015
Table United States Antidiabetic SGLT-2 Inhibitor Revenue and Market Share by Type (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Revenue Share by Type (2011-2016)
Figure Revenue Market Share of Antidiabetic SGLT-2 Inhibitor by Type (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Price by Type (2011-2016)
Figure United States Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Type (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Sales by Application (2011-2016)
Table United States Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application (2011-2016)
Figure United States Antidiabetic SGLT-2 Inhibitor Sales Market Share by Application in 2015
Table United States Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Application (2011-2016)
Figure United States Antidiabetic SGLT-2 Inhibitor Sales Growth Rate by Application (2011-2016)
Table Anderson Hay & Grain Inc. Basic Information List
Table Anderson Hay & Grain Inc. Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Figure Anderson Hay & Grain Inc. Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Border Valley Basic Information List
Table Border Valley Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Border Valley Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Sanofi Basic Information List
Table Sanofi Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Sanofi Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Johnson & Johnson Basic Information List
Table Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Johnson & Johnson Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Bristol-Myers Squibb Basic Information List
Table Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Bristol-Myers Squibb Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table AstraZeneca Basic Information List
Table AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table AstraZeneca Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Boehringer Ingelheim Basic Information List
Table Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Boehringer Ingelheim Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table GlaxoSmithKline Basic Information List
Table GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table GlaxoSmithKline Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Pfizer Basic Information List
Table Pfizer Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Pfizer Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Takeda Pharmaceuticals Basic Information List
Table Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales, Revenue, Price and Gross Margin (2011-2016)
Table Takeda Pharmaceuticals Antidiabetic SGLT-2 Inhibitor Sales Market Share (2011-2016)
Table Eli Lilly Basic Information List
Table Merck & Co. Basic Information List
Table Novo Nordisk Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Antidiabetic SGLT-2 Inhibitor
Figure Manufacturing Process Analysis of Antidiabetic SGLT-2 Inhibitor
Figure Antidiabetic SGLT-2 Inhibitor Industrial Chain Analysis
Table Raw Materials Sources of Antidiabetic SGLT-2 Inhibitor Major Manufacturers in 2015
Table Major Buyers of Antidiabetic SGLT-2 Inhibitor
Table Distributors/Traders List
Figure United States Antidiabetic SGLT-2 Inhibitor Production and Growth Rate Forecast (2016-2021)
Figure United States Antidiabetic SGLT-2 Inhibitor Revenue and Growth Rate Forecast (2016-2021)
Table United States Antidiabetic SGLT-2 Inhibitor Production Forecast by Type (2016-2021)
Table United States Antidiabetic SGLT-2 Inhibitor Consumption Forecast by Application (2016-2021)
Table United States Antidiabetic SGLT-2 Inhibitor Sales Forecast by States (2016-2021)
Table United States Antidiabetic SGLT-2 Inhibitor Sales Share Forecast by States (2016-2021)

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *